Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 106Neoplasms 14Neoplasm Metastasis 14Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Hereditary Sensory and Autonomic Neuropathies 3Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Endometrial Neoplasms 2Breast Neoplasms, Male 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Malignancies 1Recurrent Uterine Corpus Carcinoma 1Neoplasms by Site 1Lymphoma, Non-Hodgkin 1Lymphoma 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Lethal Congenital Contracture Syndrome 2 1Hyperglycemia 1Hormone Receptor Positive HER-2 Negative Breast Cancer 1Hormone Receptor Positive Breast Cancer 1HER2-positive Breast Cancer 1Female Breast Carcinoma 1Exanthema 1

Interventions

benralizumab 1Triamcinolone Acetonide 1Tetracycline 1Sirolimus 1Panitumumab 1Minocycline 1Irinotecan 1IFL protocol 1Hydrocortisone 1Gels 1Fulvestrant 1Erlotinib Hydrochloride 1Dapsone 1Clindamycin 1Anti-Bacterial Agents 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Exanthema × Fulvestrant × Clear all
NCT05966584 2024-08-29

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
1 enrolled 5 charts
Breast

Breast Neoplasms, Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡